Insider Buying: Sensei Biotherapeutics (NASDAQ:SNSE) Major Shareholder Buys 6,005 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) major shareholder Millennium Management Llc bought 6,005 shares of the business’s stock in a transaction on Tuesday, March 31st. The stock was purchased at an average cost of $28.16 per share, for a total transaction of $169,100.80. Following the transaction, the insider owned 146,657 shares of the company’s stock, valued at $4,129,861.12. This trade represents a 4.27% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Millennium Management Llc also recently made the following trade(s):

• On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $28.12, for a total value of $52,218.84.
• On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.81, for a total value of $13,539.05.
• On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total value of $23,629.68.
• On Monday, March 30th, Millennium Management Llc bought 9,533 shares of Sensei Biotherapeutics stock. The stock was purchased at an average cost of $25.86 per share, for a total transaction of $246,523.38.
• On Friday, March 27th, Millennium Management Llc bought 15,321 shares of Sensei Biotherapeutics stock. The stock was purchased at an average cost of $26.61 per share, for a total transaction of $407,691.81.
• On Thursday, March 26th, Millennium Management Llc bought 5,731 shares of Sensei Biotherapeutics stock. The stock was purchased at an average cost of $28.62 per share, for a total transaction of $164,021.22.
• On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total value of $40,554.59.
• On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total value of $36,397.50.
• On Wednesday, April 1st, Millennium Management Llc purchased 6,175 shares of Sensei Biotherapeutics stock. The stock was acquired at an average price of $34.49 per share, with a total value of $212,975.75.
• On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $32.12, for a total transaction of $246,231.92.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ:SNSE traded up $0.61 during trading on Friday, hitting $20.43. The company’s stock had a trading volume of 40,084 shares, compared to its average volume of 223,112. The business has a 50 day moving average price of $29.11 and a two-hundred day moving average price of $17.85. The company has a market capitalization of $27.40 million, a PE ratio of -1.23 and a beta of -0.18. Sensei Biotherapeutics, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $36.76.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its quarterly earnings results on Friday, May 15th. The company reported ($131.45) EPS for the quarter, missing the consensus estimate of ($0.62) by ($130.83). As a group, equities analysts expect that Sensei Biotherapeutics, Inc. will post -2.77 earnings per share for the current fiscal year.

Key Headlines Impacting Sensei Biotherapeutics

Here are the key news stories impacting Sensei Biotherapeutics this week:

• Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
• Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
• Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Zacks Research upgraded shares of Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Leerink Partners initiated coverage on shares of Sensei Biotherapeutics in a research note on Monday, April 20th. They set an “outperform” rating and a $50.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $40.00.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC increased its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 178.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,041 shares of the company’s stock after purchasing an additional 20,525 shares during the period. Renaissance Technologies LLC owned 2.39% of Sensei Biotherapeutics worth $1,010,000 at the end of the most recent quarter. 10.50% of the stock is currently owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.